TEL AVIV, Israel, March 17, 2013 /PRNewswire/ -- Elbit Imaging Ltd. (the "Company") (TASE, NASDAQ: EMITF) announced today, following requests for certain clarifications from bondholders and their representatives in connection with the proposed restructuring of the debt of the Company (the " Restructuring") described in the press release issued by the Company on February 27, 2013 (the " Prior Press Release"), the following clarifications: No Voting Agreements York Capital Management Global Advisors, LLC (" York") and Davidson Kempner Capital Management LLC (" DK", and collectively with York, the " Funds") have informed the Company that there are no voting agreements between them, nor are there any voting agreements between either of them, on the one hand, and Mordechay Zisser, the Chief Executive Officer and a director of the Company and the Company’s controlling shareholder and/or any entity in his control, on the other hand, nor do they have any current intentions to enter into such voting agreements. No Current Intentions to Raise Capital or Issue Additional Securities The Company does not have any current intentions to raise capital and/or to issue any additional securities of the Company (via a private placement, public offering or otherwise) following the completion of the Restructuring and the issuance of the New Notes and the Ordinary Shares (as set forth and described in the Prior Press Release) or in the near future thereafter nor do its current plans require such capital raising or issuance of new securities. No Additional Transactions There are no transactions currently contemplated between the Company and the Funds except as set forth in the Prior Press Release, and the Company does not have any current intentions to enter into any other such transaction. Any future transactions between the Company and the Funds will be subject to the receipt of all approvals required under applicable law and will be conducted on an arm's-length basis.
Elbit Imaging (EMITF) is rocketing higher on Tuesday after announcing its Gamida Cell Ltd, which Elbit's subsidiary Elbit Medical Technologies holds 30.8% voting power in, had received an acquisition proposal from a pharmaceutical company.